January 20, 2021 08:09 AM ESTUpdated 09:05 AM

The IPO flood keeps rising with 4 more biotechs and a SPAC on their way to Nasdaq

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

After a record year for biotech IPOs in 2020, forecasts were bullish on another strong year showing for public offerings — and 2021 hasn’t disappointed so …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

The IPO flood keeps rising with 4 more biotechs and a SPAC on their way to Nasdaq

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

Sign up to read this article for free.

Lilly drops body mass ranges from FDA label for weight loss drug

GSK terminates Phase 2 trial of HBV therapeutic vaccine

Coherus makes final, $483M pivot away from biosimilars

Janux soars on early prostate cancer data that could challenge Novartis' Pluvicto

Ipsen secures rights to preclinical T cell engager in $610M pact with French biotech

Roche teams up with Chicago autoimmune biotech COUR Pharmaceuticals

The IPO flood keeps ris­ing with 4 more biotechs and a SPAC on their way to Nas­daq

Senior Editor

Editor

Sign up to read this article for free.

more like this

The IPO flood keeps rising with 4 more biotechs and a SPAC on their way to Nasdaq